{"id":7597,"date":"2025-04-10T09:06:23","date_gmt":"2025-04-10T09:06:23","guid":{"rendered":"https:\/\/tst.incliva.es\/?page_id=7597"},"modified":"2025-04-10T09:06:23","modified_gmt":"2025-04-10T09:06:23","slug":"research-group-on-cardiometabolic-risk-and-diabetes","status":"publish","type":"page","link":"https:\/\/tst.incliva.es\/en\/que-hacemos\/areas\/cardiovascular\/research-group-on-cardiometabolic-risk-and-diabetes\/","title":{"rendered":"Research Group on Cardiometabolic Risk and Diabetes"},"content":{"rendered":"

\n
\n

Research Group on Cardiometabolic Risk and Diabetes<\/h3>\n<\/div>\n
<\/div><\/div>\n
Cardiovascular Area<\/span><\/h5>\n<\/div>\n
<\/div><\/div>\n

In terms of scientific activity of the research group during 2022, our group is participating in the development of three competitive and multidisciplinary research projects that include the following aims: <\/p>\n

– Project: Immunopharmacological modulation of the systemic inflammation associated to metabolic disorders. Search for new therapeutic targets and synthesis of novel drugs <\/p>\n

– Project: Study of new inflammatory and angiogenic mechanisms associated to severe morbid obesity <\/p>\n

– Project: Role of the inflammatory processes in metabolic diseases and associated complications <\/p>\n

– Project: Evaluation of the efficacy of pharmacogenetics to improve the response to treatment in subjects with insufficiently controlled type 2 diabetes<\/p>\n<\/div>\n<\/div><\/div>